OS
Fig. 2 · Panel C
Panel C 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Scott Kopetz, Danielle A Murphy, Jie Pu, Fortunato Ciardiello, Jayesh Desai, Eric Van Cutsem, Harpreet Singh Wasan, Takayuki Yoshino, Hedieh Saffari, Xiaosong Zhang, Phineas Hamilton, Tao Xie, Rona Yaeger, Josep Tabernero
Nat Med 30(11) 3261-3271
The BEACON CRC study demonstrated that encorafenib (Enco)+cetuximab (Cetux)±binimetinib (Bini) significantly improved overall survival (OS) versus Cetux + chemotherapy in previously treated patients with BRAF-V600E-mutant mCRC, providing the basis for the approval of the Enco+Cetux regimen in the United States and the European Union. A greater understanding of biomarkers predictive of response to Enco+Cetux±Bini treatment is of clinical relevance. In this prespecified, exploratory biomarker analysis of the BEACON CRC study, we characterize genomic and transcriptomic correlates of clinical outcomes and acquired resistance mechanisms through integrated clinical and molecular analysis, including whole-exome and -transcriptome tissue sequencing and circulating tumor DNA genomic profiling. Tumors with higher immune signatures showed a trend towards increased OS benefit with Enco+Bini+Cetux. RAS, MAP2K1 and MET alterations were most commonly acquired with Enco+Cetux±Bini, and more frequent in patients with a high baseline cell-cycle gene signature; baseline TP53 mutation was associated with acquired MET amplification. Acquired mutations were subclonal and polyclonal, with evidence of increased tumor mutation rate with Enco+Cetux±Bini and mutational signatures (SBS17a/b). These findings support treatment with Enco+Cetux±Bini for patients with BRAF-V600E-mutant mCRC and provide insights into the biology of response and resistance to MAPK-pathway-targeted therapy. ClinicalTrials.gov registration: NCT02928224.
5 个 Figure · 11 个 KM 面板
Fig. 2. Mutational profiling of patients with BRAF-V600E-mutant mCRC in BEACON CRC. a , Oncoprint showing frequency of cancer gene mutations in baseline tumors profiled by the GuardantOMNI panel, as well as TMB and MSI status (top bars), across treatment arms determined using WES. BRAF alterations included V600E and other alterations. The MSS group also included patients who were MSI-low. b , Baseline tumor size (left panel) and baseline ctDNA maxVAF (right panel) by baseline ctDNA BRAF -V600E status. P values were based on the Wilcoxon rank-sum test (two-sided). The boxes show medians and IQR; the whiskers represent 1.5 × IQR. c , Kaplan–Meier plots of OS by ctDNA BRAF- V600E VAF status (split on median) in each treatment arm. P values (two-sided Wald test) were based on the Cox model without adjustment for baseline covariates. d , Distribution of BM1 and BM2 subtypes across CMS subgroups. a The ‘not detected’ group included patients with no ctDNA detected. b Patients with no ctDNA detected were excluded from the analysis. c The BM1 subtype is characterized by high KRAS/mTOR/AKT/4EBP1, epithelial–mesenchymal transition (EMT) and immune infiltration, whereas the BM2 subtype is characterized by cell-cycle checkpoint dysregulation. d CMS1 is characterized by MSI and immune patterns and enrichment for BRAF mutations; CMS2 by chromosomal instability and WNT activation; CMS3 by metabolic pattern and enrichment for KRAS mutations and CMS4 by EMT, angiogenesis and stromal infiltration.
Fig. 2 · Panel C
Panel C 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4. Immune gene associations with OS benefit from Enco+Cetux±Bini. a , Associations between OS and immune gene expression (scaled) were determined by Cox proportional hazards models (two-sided Wald test). Genes in the top quartile of variance in expression (based on IQR and measured in log 2 (TPM)) were tested. b , GSEA hallmark genesets; highest average absolute normalized enrichment score (NES) across arms are shown; point size indicates Benjamini–Hochberg-adjusted P values from permutation testing. c , Kaplan–Meier plots of OS by cytolytic score (split on median). P values for interaction (two-sided Wald test) were based on Cox proportional hazard models with and without adjustment for baseline covariates.
Fig. 4 · Panel C
Panel C 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel C_2
Panel C_2 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 3. Kaplan–Meier plots of OS by ctDNA maxVAF status in each treatment arm. ctDNA maxVAF was categorized as ≤ or > the median of 11.005. Cox proportional hazard models with or without adjustment of baseline covariates (ECOG performance status, C-reactive protein, number of organs, tumor status, cetuximab source, and prior use of irinotecan at randomization) were used. A two-sided Wald test was used for P value of interaction terms, where ctDNA maxVAF was regarded as a continuous variable. Bini, binimetinib; Cetux, cetuximab; CI, confidence interval; ctDNA, circulating tumor DNA; ECOG, Eastern Cooperative Oncology Group; Enco, encorafenib; HR, hazard ratio; max, maximum; OS, overall survival; VAF, variant allele frequency.
Extended Data Fig. 3 · Panel OS_by_ctDNA_maxVAF_status
Panel OS_by_ctDNA_maxVAF_status 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 7. Kaplan–Meier plots of PFS by cytolytic score between and within each treatment arm. a , Kaplan–Meier plots of PFS by cytolytic score between treatment arms (inter-arm comparison). b , Kaplan–Meier plots of PFS by cytolytic score within each treatment arm (intra-arm comparison). Tumors were categorized as cytolytic high or low, defined as score > and ≤ the median value of 3.11, respectively. Cox proportional hazard models with or without adjustment of baseline covariates (ECOG performance status, C-reactive protein, number of organs, tumor status, cetuximab source, and prior use of irinotecan at randomization) were used. A two-sided Wald test was used for P value of interaction terms, where cytolytic score was regarded as a continuous variable. Bini, binimetinib; Cetux, cetuximab; CYT, cytolytic; ECOG, Eastern Cooperative Oncology Group; Enco, encorafenib; HR, hazard ratio; PFS, progression-free survival.
Extended Data Fig. 7 · Panel A
Panel A 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 7 · Panel A_2
Panel A_2 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 7 · Panel B
Panel B 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 7 · Panel B_4
Panel B_4 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 7 · Panel B_5
Panel B_5 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 9. Kaplan-Meier plots of OS by presence of top acquired alterations (top panel) or MET amplification (bottom panel) following treatment with Enco+Cetux±Bini. Cox proportional hazard models with and without adjustment of baseline covariates (ECOG performance status, C-reactive protein, number of organs, tumor status, cetuximab source, and prior use of irinotecan at randomization) were used. Bini, binimetinib; Cetux, cetuximab; CI, confidence interval; Enco, encorafenib; HR hazard ratio; OS, overall survival.
Extended Data Fig. 9 · Panel Acquired_any_top_gene_alteration
Panel Acquired_any_top_gene_alteration 是同一 Extended Data Fig. 9 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 9 · Panel Acquired_MET_amplification
Panel Acquired_MET_amplification 是同一 Extended Data Fig. 9 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。